Abstract
OBJECTIVES: In recent years, there has been a notable increase in the incidence and mortality rates of prostate cancer (PCa) in China, highlighting it as a significant public health issue. This study aimed to investigate the genetic association of PCa in China to better inform national disease management and medical resource allocation. METHODS: A systematic literature review was conducted using 5 English databases (Web of Science, PubMed, Embase, Cochrane, Scopus) and 1 Chinese database (CNKI) to identify articles published from database inception to October 8, 2022, which reported the genetic associations of PCa in China. RESULTS: Of the 11,195 articles retrieved, 41 were included in the review. A total of 116 different polymorphisms (including single nucleotide polymorphisms, deletions, insertions, and repeat lengths) in 58 genes were studied in Chinese populations. Among these, 37 out of 51 polymorphisms in 28 candidate genes such as BIRC5, C2orf43, COX-2, CYR61 (IGFBP10), DNMT1, DNMT3B, EXO1, FOXP4, and 7 unmapped SNPs were found to have either a positive or negative effect on PCa risk. However, 18 variants in 5 genes remain controversial across different studies. Additionally, 23 SNPs in 16 genes were reported to be associated with disease stage, Gleason score, PSA levels, PCa risk, and clinicopathological characteristics of PCa in China. CONCLUSION: In Chinese populations, PCa risk and clinical features may result from individual genes, gene-gene interactions, and gene-environment interactions. These findings provide important insights into the relationship between genetic susceptibility and PCa risk in Chinese men.